The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1001
Troglitazone for Non-Insulin-Dependent Diabetes Mellitus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Troglitazone for Non-Insulin-Dependent Diabetes Mellitus
Troglitazone (Rezulin - Parke-Davis), the first of a new class of thiazolidinedione derivatives ('glitazones') for diabetes, has been marketed for oral treatment of noninsulin- dependent diabetes mellitus (NIDDM) in patients who take more than 30...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Troglitazone for Non-Insulin-Dependent Diabetes Mellitus
Article code: 1001a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.